Publicacions en col·laboració amb investigadors/es de Hospital de Fuenlabrada (8)

2023

  1. External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification

    European Journal of Surgical Oncology, Vol. 49, Núm. 8, pp. 1481-1488

  2. Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3378-3394

2022

  1. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases

    BMC Cancer, Vol. 22, Núm. 1

2020

  1. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP)

    Clinical and Translational Oncology, Vol. 22, Núm. 1, pp. 130-136

2017

  1. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

    Clinical and Translational Oncology, Vol. 19, Núm. 11, pp. 1388-1392

2016

  1. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study

    Surgical Oncology, Vol. 25, Núm. 2, pp. 111-116

2012

  1. Hyperthermic Intraperitoneal Chemotherapy. Methodology and Safety Considerations

    Surgical Oncology Clinics of North America, Vol. 21, Núm. 4, pp. 543-557

2007

  1. Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals

    Clinical and Translational Oncology, Vol. 9, Núm. 10, pp. 652-662